Daiichi Sankyo and ArQule are discontinuing a Phase III trial of tivantinib in combination with erlotinib for patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC). The trial showed significant improvements in time to progression but the companies did not see similar results in patients’ overall survival, ArQule CEO Paolo Pucci said during a conference call.
Washington Drug Letter